An innovative phase 2 clinical trial designed to find new potential treatments for glioblastoma has reported initial results. While none of the three therapeutics tested so far improved overall survival of patients, this adaptive platform trial, the first of its kind in neuro-oncology, has the potential to rapidly and efficiently identify therapies that benefit patients.
